Notably, a TβRI inhibitor or TGF-β-neutralizing antibodies can prevent VEGF and IL-6 production and reduce MM cell proliferation and cell adhesion to BMSCs. This evidence concerns the gene TGFB1 and Miyoshi myopathy.